Omada Health
Virtual chronic-care platform with weight health, GLP-1 companion programs, diabetes, hypertension, MSK, and behavior-change support. Strong B2B distribution with integrated care journeys.
Access model
Mostly through employers, health plans, and health systems
Editorial note
One of the strongest enterprise evidence stories in the cohort.
Coverage and cost
Generally yes via employer/health-plan benefit
Not publicly disclosed; sponsor-specific
No public emphasis; public positioning centers on behavior change plus FDA-approved GLP-1 support
Market signals
Evidence and positioning
Public 2026 outcomes: 18.4% average 1-year weight loss for members persistent on GLP-1s, 13.1% for members who discontinued before 1 year, and 16.3% across all members in the program. Omada also published post-discontinuation maintenance analyses.
This is the lower dB's current read on Omada Health's pricing posture, insurance story, medication posture, and evidence signaling.
Source References
5 public references used in this profile. Links open in a new tab for quick verification.
Pricing, insurance coverage, medication availability, and eligibility can change quickly. Verify current details directly with the provider before starting or switching care.